← Eichor
Study identifier: NCT06938750 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Novel Medical Device for Pharmacological Therapy

Condition: Vascular Access · Vascular Access Complication · Vascular Access Complications  ·  Sponsor: Fundacion Miguel Servet

PhaseNA
Planned participants262
Who can joinAll sexes, 1 Year to no upper limit
Healthy volunteersNo

About this study

Background: Different co-creation methods were used to design and prototype a new fixative device for multiple intravenous therapies with the ability to control and identify the pharmacological therapy administered to a patient. Objectives: To validate a newly created device for the reduction of complications related to the use of intravenous therapy Methods: A multidisciplinary team composed of eight professionals specializing in the field of critical care and an engineering professional in industrial design was responsible for collecting, evaluating, and materializing the ideas and needs arising from clinical practice in a device that met the standards of the same.

This description comes directly from the study's public registry record.

Talk to the study team

marta M FERRAZ-TORRES, PHD  ·  +34628813974  ·  marta.ferraz.torres@navarra.es

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Universitario de NavarraPamplona, Navarre, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06938750